StockData
AbbVie Inc. logo

AbbVie Inc. (ABBV) stock

ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 10/3090% above fair value
$292.82−1.73 (-0.59%)

Close on Nov 17, 2026Market cap $517.45BP/E 82.7Yield 2.27%

AbbVie total assets

Total assets on the balance sheet at the end of each period.

AbbVie's total assets was $135.12B at Jun 30, 2026. For fiscal 2025 it was $133.96B, down 0.9% from the year before. Over ten years it grew 9.7% a year on average. The highest annual figure on record is $150.57B in fiscal 2020.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$133.96B-0.9%
FY2024Dec 31, 2024$135.16B+0.3%
FY2023Dec 31, 2023$134.71B-2.9%
FY2022Dec 31, 2022$138.81B-5.3%
FY2021Dec 31, 2021$146.53B-2.7%
FY2020Dec 31, 2020$150.57B+69.0%
FY2019Dec 31, 2019$89.12B+50.1%
FY2018Dec 31, 2018$59.35B-16.2%
FY2017Dec 31, 2017$70.79B+7.1%
FY2016Dec 31, 2016$66.10B+24.6%
FY2015Dec 31, 2015$53.05B+92.8%
FY2014Dec 31, 2014$27.51B-5.8%
FY2013Dec 31, 2013$29.20B+8.1%
FY2012Dec 31, 2012$27.01B–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$135.12B-1.5%
Q1 FY2026Mar 31, 2026$136.46B+0.2%
Q4 FY2025Dec 31, 2025$133.96B-0.9%
Q3 FY2025Sep 30, 2025$133.90B-6.6%
Q2 FY2025Jun 30, 2025$137.18B-3.4%
Q1 FY2025Mar 31, 2025$136.17B-8.5%
Q4 FY2024Dec 31, 2024$135.16B+0.3%
Q3 FY2024Sep 30, 2024$143.42B+5.3%
Q2 FY2024Jun 30, 2024$141.94B+4.9%
Q1 FY2024Mar 31, 2024$148.87B+10.7%
Q4 FY2023Dec 31, 2023$134.71B-2.9%
Q3 FY2023Sep 30, 2023$136.22B-3.6%
Q2 FY2023Jun 30, 2023$135.37B-5.5%
Q1 FY2023Mar 31, 2023$134.54B-6.1%
Q4 FY2022Dec 31, 2022$138.81B-5.3%
Q3 FY2022Sep 30, 2022$141.33B-5.1%
Q2 FY2022Jun 30, 2022$143.19B-3.2%
Q1 FY2022Mar 31, 2022$143.21B-4.8%
Q4 FY2021Dec 31, 2021$146.53B-2.7%
Q3 FY2021Sep 30, 2021$148.86B-0.5%
Q2 FY2021Jun 30, 2021$147.97B-1.0%
Q1 FY2021Mar 31, 2021$150.50B+65.0%
Q4 FY2020Dec 31, 2020$150.57B+69.0%
Q3 FY2020Sep 30, 2020$149.62B+151.7%
Q2 FY2020Jun 30, 2020$149.53B+161.7%
Q1 FY2020Mar 31, 2020$91.20B+60.6%
Q4 FY2019Dec 31, 2019$89.12B+50.1%
Q3 FY2019Sep 30, 2019$59.44B-10.2%
Q2 FY2019Jun 30, 2019$57.14B-7.3%
Q1 FY2019Mar 31, 2019$56.77B-18.1%
Q4 FY2018Dec 31, 2018$59.35B-16.2%
Q3 FY2018Sep 30, 2018$66.16B-3.9%
Q2 FY2018Jun 30, 2018$61.64B-8.0%
Q1 FY2018Mar 31, 2018$69.34B+5.6%
Q4 FY2017Dec 31, 2017$70.79B+7.1%
Q3 FY2017Sep 30, 2017$68.84B+3.3%
Q2 FY2017Jun 30, 2017$66.99B–
Q1 FY2017Mar 31, 2017$65.66B–
Q4 FY2016Dec 31, 2016$66.10B–
Q3 FY2016Sep 30, 2016$66.63B–

More AbbVie figures

See a number that looks wrong?